ALN-APOC3 Investigational APOC3-silencing RNAi therapy licensed to Regeneron, undergoing Phase 1 clinical development for people with dyslipidemia and abnormal lipid levels.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-APOC3.
Add it to your Products I use list and share why you use it.